

# Resonance Health Limited

ASX: RHT

Annual General Meeting  
27<sup>th</sup> November 2014




# Resonance Health Limited

---

- ✓ ASX Listed: RHT
- ✓ RHT develops patent-protected medical image analysis software for the assessment of various liver disease conditions
  - RHT provides image analysis services in +25 countries
  - RHT provides imaging core laboratory services for clinical trials
- ✓ Market capitalisation ~ AU\$19m, (401,202,567 shares on issue)
- ✓ AU\$2.0m raised by the issue of 40.2m shares via a right issue and placement
- ✓ Net loss reported \$72k for 2013/14 financial year
- ✓ Expected profit for half year to Dec 2014 (~\$150k)
- ✓ Cash on hand at 30 September of \$2,640,000



# Products / Pipeline



- Liver disease is the only major cause of death still increasing in the UK
- Liver disease is one of the top 10 causes of death in the US



# Year in Review

---


- ✓ **50% increase** in sales revenue year on year
- ✓ **50+ new radiology facilities** starting using FerriScan during the year
- ✓ **33% increase** in the number of referring clinicians
- ✓ **23 consecutive months** of year on year sales volume growth
- ✓ FDA, TGA and CE Mark **regulatory clearance** to market HepaFat-Scan for fatty liver disease diagnosis
- ✓ **US market assessment** completed for HepaFat-Scan
- ✓ **Pilot customer** use of HepaFat-Scan commenced
- ✓ HepaFat-Scan wins **Innovator of the Year Award**



# Strong growth year on year

- 32% increase in volume
- Over 5,500 image analyses performed during FY 2013/14

**Annual Image Analysis Volumes**



Double digit annual growth in volumes



# Services Business Unit

---


- ✓ 50% increase in revenue (AU\$2.3m)
  - Image analysis services
  - Clinical trial project management services
- ✓ 50+ new MRI facilities providing FerriScan®
  - FerriScan became available in 6 new countries: Algeria, Bulgaria, Israel, Kuwait, Morocco and South Africa
  - 14 new centres in the UK
  - 11 new centres in Australia
  - 8 new centres in Italy
  - 7 new centres in the USA
- ✓ Profitable business unit

~80% of the volume of work performed was for routine clinical use (not clinical trials)



# Global Access to FerriScan

---




Some FerriScan® locations, 250+ have been activated



# HepaFat-Scan®

- ✓ New product launched in 2014
- ✓ Provides a measurement of the % of the liver that is fat
- ✓ FDA, TGA and CE Mark cleared for marketing
- ✓ Patent application lodged
- ✓ Completed a US market opportunity assessment:
  - **Surgery planning** for patients with liver cancer
  - Liver fat assessment for living donor **liver transplants**
  - Diagnosis of non-alcoholic fatty liver disease (**NAFLD**)
  - **Clinical trials** for drugs in development for the treatment of NAFLD






# Non-alcoholic fatty liver disease

- **Epidemic** in many western and developing countries with significant health implications

- Approximately **30%** of the US population has fatty liver disease



- Fatty liver disease is a dominant cause of **liver cancer**
- Fatty liver disease is the **#1 risk factor for cardio vascular disease**
- Fatty liver can lead to liver inflammation, **fibrosis** and cirrhosis
- Fatty liver disease is closely associated with **Type 2 diabetes**
- NAFLD is expected to be the leading cause of liver transplants by 2020
- New drugs are in development to address this market, which require a diagnostic tool



# HepaFat-Scan®

---

- Current diagnostics are invasive (liver biopsy) or don't measure the amount of fat in the liver (ultrasound)
- HepaFat-Scan provides a **measurement** of the fraction of the liver that is fat
- HepaFat-Scan is **non-invasive** using MRI scanners
- HepaFat-Scan works across **different scanner** makes and models
- HepaFat-Scan is now being **piloted** by some of our customers
- **Two studies being planned** to demonstrate the value of HepaFat-Scan:
  - Jan 2015 plan to commence a pediatric study in the US
  - March 2015 plan to commence a liver surgery study using HepaFat-Scan
- Active discussions in progress with **pharmaceutical companies** developing new drugs to address fatty liver disease



# Liver Fibrosis Pipeline Project

---

- Pipeline product in development to measure liver fibrosis using MRI imaging
- Collaborating with the University of Western Australia and other researchers
- Results are promising
- HepaFat-Scan studies in 2015 will include liver fibrosis research
- Market for an MRI based diagnostic for liver fibrosis is very large
  - Liver fibrosis (scarring) is caused by fatty liver disease, viral hepatitis (affecting 170m), iron overload and excess alcohol consumption
  - Liver fibrosis can progress to liver cirrhosis - one of the top 10 causes of death in the USA and is a significant predictor of liver cancer
  - Pharmaceutical companies and clinicians need access to an accurate non-invasive diagnostic tool to assess liver fibrosis



# Summary

---

- ✓ Strong growth in FerriScan sales volumes
- ✓ Strong growth in revenue
- ✓ Significant increase in number of FerriScan sites
- ✓ Partnerships with pharmaceutical companies enabling clinicians to access FerriScan for better patient management
- ✓ HepaFat-Scan gained regulatory approval
- ✓ HepaFat-Scan launched in UK and USA and with existing customer base
- ✓ HepaFat-Scan wins Innovator of the Year award
- ✓ Liver fibrosis research and development continuing with positive results to date
- ✓ Capital raising completed, cash on hand



End of presentation



# Resolutions



# Proxy Results Resolution 1

## Adoption of the Remuneration Report

For	Against	Abstaining	Discretionary
31,488,418	1,532,573	73,480,734	205,226



# Proxy Results

## Resolution 2

### Re-election of Mr Simon Panton as a Director

For	Against	Abstaining	Discretionary
105,950,167	550,000	1,558	205,226





# Proxy Results Resolution 3

## Adoption of Employee Share Plan

For	Against	Abstaining	Discretionary
101,590,412	4,916,005	1,558	198,976



# Close of meeting

